{"id":5008,"date":"2025-12-10T16:54:57","date_gmt":"2025-12-10T16:54:57","guid":{"rendered":"https:\/\/regenerated.health\/does-ketamine-therapy-get-you-high\/"},"modified":"2026-06-25T14:07:34","modified_gmt":"2026-06-25T14:07:34","slug":"does-ketamine-therapy-get-you-high","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/does-ketamine-therapy-get-you-high\/","title":{"rendered":"Does Ketamine Therapy Get You High?"},"content":{"rendered":"\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div><\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our full pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our complete pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our complete pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- \/wp:group --><!-- \/wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our full pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our complete pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our complete pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- \/wp:group --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our full pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:post-content --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our in-depth pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- \/wp:group --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our detailed pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:group --><!-- \/wp:group --><!-- wp:post-content --><!-- wp:group {\"style\":{\"color\":{\"background\":\"#f0f7f4\"},\"border\":{\"radius\":\"12px\"},\"spacing\":{\"padding\":{\"top\":\"30px\",\"right\":\"30px\",\"bottom\":\"30px\",\"left\":\"30px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\">\n\n<h3 class=\"wp-block-heading\" style=\"font-size:22px\">At a Glance<\/h3>\n\n<ul class=\"wp-block-list\">\n<li><strong>Short answer:<\/strong> Clinical ketamine produces altered perception and dissociation &#8211; but the experience is fundamentally different from a recreational &#8220;high.&#8221;<\/li>\n<li><strong>What patients feel:<\/strong> Floating sensations, dreamlike states, mild visual distortions, a sense of detachment from the body. Most describe it as &#8220;strange&#8221; rather than &#8220;euphoric.&#8221;<\/li>\n<li><strong>Dose matters:<\/strong> Sub-anesthetic doses (0.5 mg\/kg IV) produce mild-to-moderate dissociation &#8211; far below what recreational users seek.<\/li>\n<li><strong>Addiction risk:<\/strong> Very low at clinical doses and frequencies. Monitored settings with limited access reduce misuse potential significantly.<\/li>\n<li><strong>Key takeaway:<\/strong> The psychoactive experience is not a side effect to endure &#8211; emerging evidence suggests the dissociative state may actually contribute to therapeutic outcomes.<\/li>\n<\/ul>\n\n<\/div>\n\n<!-- wp:separator {\"className\":\"is-style-wide\"} -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n<!-- \/wp:separator -->\n\n<p>This is one of the most common questions people ask before starting ketamine therapy &#8211; and it deserves an honest answer. Not a sanitized clinical deflection. Not a scare-tactic warning. An honest one.<\/p>\n\n<p>Yes, ketamine is psychoactive. Yes, you will feel something during your session. No, it is not the same as getting high at a party. The distinction matters, and understanding it can actually reduce anxiety about treatment and help you get more out of the experience.<\/p>\n\n<p>If you are considering <a href=\"\/blog\/ketamine-therapy\/\">ketamine therapy<\/a> for depression, PTSD, anxiety, or chronic pain, here is what the clinical experience actually feels like &#8211; and why the altered state may be a feature, not a bug.<\/p>\n\n<h2 class=\"wp-block-heading\">What Ketamine Actually Does to the Brain<\/h2>\n\n<p>Ketamine is an NMDA receptor antagonist. In simple terms, it temporarily blocks a specific type of glutamate receptor in the brain, which disrupts normal patterns of neural communication. This disruption produces two distinct effects that are relevant to therapy.<\/p>\n\n<p>First, there is the <strong>neurobiological effect<\/strong>. Ketamine triggers a rapid increase in brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis &#8211; the formation of new neural connections. This is what drives the antidepressant effect that can begin within hours of a single infusion. This process happens regardless of whether you &#8220;feel&#8221; anything during the session.<\/p>\n\n<p>Second, there is the <strong>psychoactive effect<\/strong>. The same NMDA blockade that triggers neuroplasticity also produces the subjective experience of dissociation &#8211; the feeling of being detached from your body, altered perception of time and space, and dreamlike mental imagery. This is what people mean when they ask if ketamine gets you high.<\/p>\n\n<p>These two effects are not separate &#8211; they are intertwined. And as researchers are discovering, the subjective experience may play a more important role in therapeutic outcomes than originally thought.<\/p>\n\n<h2 class=\"wp-block-heading\">The Clinical Experience vs. the Recreational Experience<\/h2>\n\n<p>When someone uses ketamine recreationally, they are typically taking much higher doses &#8211; often 100-300 mg or more &#8211; with the explicit goal of achieving intense dissociation or a &#8220;K-hole&#8221; (a state of near-complete detachment from reality). The setting is uncontrolled. The intention is escape or euphoria. The doses are unmonitored and frequently repeated.<\/p>\n\n<p>Clinical ketamine therapy looks nothing like this.<\/p>\n\n<!-- wp:table -->\n<figure class=\"wp-block-table\"><table><thead><tr><th>Factor<\/th><th>Recreational Use<\/th><th>Clinical Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Typical dose<\/strong><\/td><td>100-300+ mg (variable, uncontrolled)<\/td><td>0.5 mg\/kg IV (~35 mg for a 70 kg person)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Snorted, injected, or oral (unpredictable absorption)<\/td><td>IV infusion over 40 min, IM injection, or nasal (Spravato)<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>Uncontrolled &#8211; parties, homes<\/td><td>Medical clinic with monitoring<\/td><\/tr><tr><td><strong>Vital sign monitoring<\/strong><\/td><td>None<\/td><td>Continuous (BP, HR, SpO2)<\/td><\/tr><tr><td><strong>Frequency<\/strong><\/td><td>Often repeated daily or multiple times per week<\/td><td>2-3x\/week for 2-3 weeks, then monthly maintenance<\/td><\/tr><tr><td><strong>Intention<\/strong><\/td><td>Euphoria, escape, social use<\/td><td>Treat depression, PTSD, anxiety, chronic pain<\/td><\/tr><tr><td><strong>Addiction risk<\/strong><\/td><td>Moderate to high with repeated use<\/td><td>Very low at clinical doses and frequencies<\/td><\/tr><tr><td><strong>Psychological support<\/strong><\/td><td>None<\/td><td>Pre-session preparation, post-session integration<\/td><\/tr><\/tbody><\/table><\/figure>\n<!-- \/wp:table -->\n\n<p>The difference is not just semantic. It is pharmacological, contextual, and experiential. A sub-anesthetic infusion at 0.5 mg\/kg produces a qualitatively different experience than a 200 mg recreational dose. Calling both &#8220;getting high&#8221; is like comparing a glass of wine with dinner to binge drinking &#8211; technically both involve alcohol, but the experience, intent, and risk profile are entirely different.<\/p>\n\n<h2 class=\"wp-block-heading\">What Patients Actually Report Feeling<\/h2>\n\n<p>Patients describe the clinical ketamine experience in a remarkably consistent way across studies and anecdotal reports. The most common descriptions include:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Floating or weightlessness<\/strong> &#8211; a sense that the body is lighter or drifting, similar to being in water<\/li>\n<li><strong>Dreamlike imagery<\/strong> &#8211; visual patterns, colors, or scenes that feel like a vivid dream rather than a hallucination<\/li>\n<li><strong>Time distortion<\/strong> &#8211; a 40-minute infusion may feel like 10 minutes or 2 hours<\/li>\n<li><strong>Emotional distance<\/strong> &#8211; difficult memories or feelings may arise but feel &#8220;observed&#8221; rather than overwhelming<\/li>\n<li><strong>Altered body perception<\/strong> &#8211; limbs may feel larger, smaller, or blurred in boundary<\/li>\n<li><strong>A sense of insight<\/strong> &#8211; some patients report sudden clarity about problems or patterns in their life<\/li>\n<\/ul>\n\n<p>What patients overwhelmingly do <em>not<\/em> report at clinical doses is euphoria. The word that comes up most often in qualitative studies is &#8220;strange&#8221; or &#8220;weird&#8221; &#8211; not &#8220;amazing&#8221; or &#8220;fun.&#8221; Some patients find the experience mildly uncomfortable, particularly during their first session. Others find it deeply meaningful. Very few describe it as a recreational high.<\/p>\n\n<p>A 2020 study published in the <em>Journal of Psychopharmacology<\/em> found that patients receiving IV ketamine for depression rated the experience as &#8220;psychologically rich&#8221; but not &#8220;pleasurable&#8221; in the way recreational drugs are typically described. The dissociative quality was perceived more as a therapeutic tool than a source of enjoyment.<\/p>\n\n<h2 class=\"wp-block-heading\">Does the Dissociation Actually Help?<\/h2>\n\n<p>This is where the science gets genuinely interesting. For years, the working assumption was that ketamine&#8217;s antidepressant effect was purely neurobiological &#8211; it triggers BDNF release and synaptogenesis, and the psychoactive experience is just a side effect to tolerate.<\/p>\n\n<p>That assumption is being challenged.<\/p>\n\n<p>Multiple studies have now found a correlation between the degree of dissociation during a ketamine session and the magnitude of the antidepressant response. A 2021 study in the <em>American Journal of Psychiatry<\/em> reported that patients who experienced greater acute dissociation during ketamine infusion showed larger and more sustained improvements in depression scores.<\/p>\n\n<p>This does not mean you need to have an intense experience for ketamine to work. The neurobiological mechanisms operate regardless. But it does suggest that the altered state of consciousness may facilitate therapeutic processing &#8211; allowing patients to view entrenched thought patterns from a new perspective, access emotions that are normally defended against, or experience a sense of psychological &#8220;reset.&#8221;<\/p>\n\n<p>In clinics that offer psychotherapy-assisted ketamine treatment, therapists use the dissociative window as an opportunity for guided introspection. Patients may explore difficult topics during the session in a state of reduced emotional reactivity, then integrate those insights in follow-up therapy.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff3e0\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ff9800\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-color:#ff9800;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Safety Monitoring During Ketamine Sessions<\/h4>\n\n<p>Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous vital sign monitoring:<\/strong> Blood pressure, heart rate, and oxygen saturation throughout the infusion<\/li>\n<li><strong>Trained medical staff present:<\/strong> A physician, nurse practitioner, or registered nurse should be physically present during the session<\/li>\n<li><strong>Pre-screening:<\/strong> Blood pressure check, medication review, and mental health assessment before every session<\/li>\n<li><strong>Post-session observation:<\/strong> Patients should remain in the clinic for at least 30 minutes after the infusion ends and until dissociative effects have resolved<\/li>\n<li><strong>No driving policy:<\/strong> Patients must arrange transportation &#8211; no driving for 12-24 hours after a session<\/li>\n<li><strong>Emergency protocols:<\/strong> Access to resuscitation equipment and medications to manage hypertensive or adverse psychological reactions<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Dose and the Spectrum of Dissociation<\/h2>\n\n<p>The intensity of the psychoactive experience is directly dose-dependent. Understanding the dose-response spectrum helps set realistic expectations:<\/p>\n\n<p><strong>Low dose (0.25-0.4 mg\/kg IV):<\/strong> Mild relaxation, slight perceptual changes, feeling &#8220;floaty.&#8221; Patients remain conversational and oriented. Some clinics start here for anxious patients.<\/p>\n\n<p><strong>Standard therapeutic dose (0.5 mg\/kg IV over 40 minutes):<\/strong> Moderate dissociation. Dreamlike imagery, time distortion, altered body awareness. Patients can respond to questions but may prefer to remain quiet. This is the most studied dose for depression.<\/p>\n\n<p><strong>Higher therapeutic doses (0.75-1.0 mg\/kg IV):<\/strong> Stronger dissociation. More vivid imagery, deeper detachment. Used by some clinics for treatment-resistant cases or for patients who did not respond at 0.5 mg\/kg. Closer to what is described as an &#8220;ego dissolution&#8221; experience.<\/p>\n\n<p><strong>Recreational\/anesthetic doses (1.5+ mg\/kg):<\/strong> Profound dissociation or &#8220;K-hole.&#8221; Complete detachment from reality. This is NOT used in outpatient therapeutic settings.<\/p>\n\n<p>Most clinical protocols start at the standard 0.5 mg\/kg dose and adjust based on response and tolerability. The goal is not to maximize dissociation but to find the dose that produces the best therapeutic outcome with acceptable subjective effects.<\/p>\n\n<h2 class=\"wp-block-heading\">Addiction Risk at Clinical Doses<\/h2>\n\n<p>Concern about addiction is understandable &#8211; ketamine is a Schedule III controlled substance, and recreational ketamine misuse is a real phenomenon. But the addiction risk profile at clinical doses and frequencies is very different from recreational use.<\/p>\n\n<p>Several factors dramatically reduce addiction risk in clinical settings:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Controlled access:<\/strong> Patients do not take ketamine home (except in some at-home protocols with sublingual lozenges). The medication is administered in a clinic.<\/li>\n<li><strong>Low frequency:<\/strong> Treatment protocols typically involve 6 sessions over 2-3 weeks, then monthly maintenance. Addiction develops with frequent, repeated exposure &#8211; not intermittent clinical use.<\/li>\n<li><strong>Sub-anesthetic doses:<\/strong> The doses used therapeutically produce mild-to-moderate dissociation, not the intense euphoria that drives compulsive redosing.<\/li>\n<li><strong>Medical oversight:<\/strong> Clinicians monitor for signs of misuse, dose escalation, or psychological dependence.<\/li>\n<\/ul>\n\n<p>A 2019 review in <em>Neuropsychopharmacology<\/em> concluded that ketamine administered in controlled clinical protocols carries a &#8220;low risk of abuse&#8221; &#8211; comparable to or lower than benzodiazepines, which are routinely prescribed for anxiety.<\/p>\n\n<p>That said, patients with a history of substance use disorders should discuss this with their provider before starting treatment. Most clinics will still treat these patients but with additional monitoring and safeguards.<\/p>\n\n<!-- wp:group {\"style\":{\"color\":{\"background\":\"#fff8e1\"},\"border\":{\"radius\":\"12px\",\"width\":\"2px\",\"color\":\"#ffcc02\"},\"spacing\":{\"padding\":{\"top\":\"25px\",\"right\":\"25px\",\"bottom\":\"25px\",\"left\":\"25px\"}}}} -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-color:#ffcc02;border-width:2px;border-radius:12px;padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px\">\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">What to Tell Yourself Before Your First Session<\/h4>\n\n<p>If you are nervous about the psychoactive effects, here is what experienced clinicians tell their patients:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>The experience is temporary &#8211; it begins 5-10 minutes into the infusion and resolves within 15-30 minutes after it ends<\/li>\n<li>You will not lose control. At therapeutic doses, you remain aware that you are in a clinic receiving treatment<\/li>\n<li>There is no &#8220;right&#8221; way to experience ketamine. Some sessions are deeply meaningful, others feel like a foggy nap. Both can be therapeutically effective<\/li>\n<li>Lean into the experience rather than resisting it. Resistance tends to increase anxiety. Acceptance tends to produce a more comfortable session<\/li>\n<\/ul>\n\n<\/div>\n\n<h2 class=\"wp-block-heading\">Preparing for What You Will Feel<\/h2>\n\n<p>Clinics that produce the best outcomes invest time in preparation. Before your first session, a good clinic will:<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Explain exactly what to expect, including the timeline of effects (onset, peak, resolution)<\/li>\n<li>Discuss your intention for treatment &#8211; what you hope to address and any specific fears<\/li>\n<li>Create a comfortable environment &#8211; dim lighting, eye mask, music or white noise, a reclining chair or bed<\/li>\n<li>Remind you that you can communicate with staff at any time during the session<\/li>\n<li>Plan for integration &#8211; how you will process the experience afterward, either with a therapist or through journaling<\/li>\n<\/ul>\n\n<p>Preparation significantly reduces anxiety and improves the overall experience. Patients who walk into their first session with realistic expectations and a sense of safety consistently report better experiences than those who are under-informed.<\/p>\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n<h3 class=\"wp-block-heading\">Will I hallucinate during ketamine therapy?<\/h3>\n<p>At standard clinical doses (0.5 mg\/kg IV), true hallucinations are uncommon. Patients are more likely to experience dreamlike imagery &#8211; patterns, colors, or abstract scenes &#8211; with eyes closed. This is different from the vivid, reality-replacing hallucinations associated with higher doses or other psychedelic substances. Most patients describe the visual experience as subtle and internal, not overwhelming.<\/p>\n\n<h3 class=\"wp-block-heading\">Can I become addicted to clinical ketamine therapy?<\/h3>\n<p>The risk is very low when ketamine is administered in a controlled clinical setting at therapeutic doses and frequencies. Addiction develops with frequent, high-dose, unsupervised use &#8211; the opposite of how clinical protocols are structured. Patients with a history of substance use disorders should discuss this with their prescriber, but most clinicians consider clinical ketamine safe even for this population with appropriate monitoring.<\/p>\n\n<h3 class=\"wp-block-heading\">What if I have a &#8220;bad trip&#8221; during a ketamine session?<\/h3>\n<p>Difficult experiences during ketamine therapy can occur &#8211; sometimes patients encounter uncomfortable emotions or unsettling imagery. Unlike recreational use, you are in a monitored clinical setting where staff can intervene. Clinicians can slow or stop the infusion, provide verbal reassurance, or administer medication to reduce anxiety if needed. Research also suggests that difficult experiences, when properly integrated with a therapist afterward, can sometimes be the most therapeutically productive sessions.<\/p>\n\n<h3 class=\"wp-block-heading\">Does the psychoactive effect wear off with repeated sessions?<\/h3>\n<p>Some patients report that the dissociative intensity decreases slightly over the course of a treatment series, while the antidepressant effect remains. This is consistent with some degree of tolerance to the psychoactive component. Clinicians may adjust the dose upward if the therapeutic response also diminishes, but this is done carefully and is distinct from the dose escalation seen in recreational misuse.<\/p>\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/ketamine-therapy\/\">Ketamine Therapy: The Complete Guide<\/a> &#8211; our complete pillar guide covering types, protocols, costs, and evidence<\/li>\n<\/ul><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"<p>Safety Monitoring During Ketamine Sessions Every clinical ketamine session should include the following safety measures &#8211; if a clinic does not provide these, that is a red flag: Continuous vital sign monitoring: Blood pressure, heart rate, and oxygen saturation throughout the infusion Trained medical staff present: A physician, nurse practitioner, or registered nurse should be&#8230;<\/p>\n","protected":false},"author":1,"featured_media":6216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1002,992],"tags":[],"class_list":["post-5008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ketamine-psychedelic-therapy","category-treatments"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5008"}],"version-history":[{"count":2,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5008\/revisions"}],"predecessor-version":[{"id":5309,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5008\/revisions\/5309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/6216"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}